

RESEARCH

Open Access

# Effect of a multivitamin preparation supplemented with phytosterol on serum lipids and infarct size in rats fed with normal and high cholesterol diet

Tamás Csont<sup>1,2</sup>, Márta Sárközy<sup>1,2</sup>, Gergő Szűcs<sup>1</sup>, Csilla Szűcs<sup>3</sup>, Judit Bárkányi<sup>3</sup>, Péter Bencsik<sup>1,2</sup>, Renáta Gáspár<sup>1</sup>, Imre Földesi<sup>4</sup>, Csaba Csonka<sup>1,2</sup>, Csaba Kónya<sup>3</sup> and Péter Ferdinandy<sup>2,5\*</sup>

## Abstract

**Background:** Although complex multivitamin products are widely used as dietary supplements to maintain health or as special medical food in certain diseases, the effects of these products were not investigated in hyperlipidemia which is a major risk factor for cardiovascular diseases. Therefore, here we investigated if a preparation developed for human use containing different vitamins, minerals and trace elements enriched with phytosterol (VMTP) affects the severity of experimental hyperlipidemia as well as myocardial ischemia/reperfusion injury.

**Methods:** Male Wistar rats were fed a normal or cholesterol-enriched (2% cholesterol + 0.25% cholate) diet for 12 weeks to induce hyperlipidemia. From week 8, rats in both groups were fed with a VMTP preparation or placebo for 4 weeks. Serum triglyceride and cholesterol levels were measured at week 0, 8 and 12. At week 12, hearts were isolated, perfused according to Langendorff and subjected to a 30-min coronary occlusion followed by 120 min reperfusion to measure infarct size.

**Results:** At week 8, cholesterol-fed rats showed significantly higher serum cholesterol level as compared to normal animals, however, serum triglyceride level did not change. VMTP treatment significantly decreased serum cholesterol level in the hyperlipidemic group by week 12 without affecting triglyceride levels. However, VMTP did not show beneficial effect on infarct size. The inflammatory marker hs-CRP and the antioxidant uric acid were also not significantly different.

**Conclusions:** This is the first demonstration that treatment of hyperlipidemic subjects with a VMTP preparation reduces serum cholesterol, the major risk factor for cardiovascular disease; however, it does not provide cardioprotection.

**Keywords:** Multivitamin, Multimineral, Prevention, Hypercholesterolemia, Cardiovascular risk, Inflammation, Oxidative stress

## Background

Large clinical studies showed that a significant population of adults is affected by hyperlipidaemia in the developed countries [1]. In the USA, approximately 100 million people (44.4%) suffered from hypercholesterolemia (>200 mg/dL) in 2008 [2]. It is well known, that hyperlipidemia, especially hypercholesterolemia is a major risk

factor in the development of atherosclerosis and subsequent ischemic heart disease [3] which is a leading cause of death in industrialized countries [4]. Moreover, several experimental studies have demonstrated that in addition to its well-known pro-atherogenic effect in the vasculature, hyperlipidemia may directly affect the heart causing contractile dysfunction [5,6] and attenuated responses to cardioprotective interventions [7-10].

It has been shown in large clinical trials that antihyperlipidemic agents e.g. statins [11], fibrates [12], and niacin [13] could reduce the incidence of cardiovascular events in hypercholesterolemic patients [11].

\* Correspondence: peter.ferdinandy@pharmahungary.com

<sup>2</sup>Pharmahungary Group, Szeged, Hungary

<sup>5</sup>Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Full list of author information is available at the end of the article

Therefore, development of anti-hyperlipidemic strategies is a crucial point in reducing the risk of coronary heart disease.

Regular consumption of multivitamin and multimineral supplements is common in developed countries [14] to maintain general health. In the United States, more than half of the adult population use dietary supplements [15] primarily in the form of multivitamins with or without minerals [16]. In 1998 a study reported that in Germany 18% of men and 25% of women were regular users of multivitamins among 18–79 years old adults [17]. Moreover, sales data show increasing consumption of these products both in the USA and Europe. The effect of these complex multivitamin preparations on hyperlipidemia and its consequences is, however, not well understood.

Not only total energy intake and macronutrients including carbohydrates, protein and fat, but also micronutrients including vitamins, minerals and trace elements may affect the severity of hyperlipidaemia. A few clinical and experimental studies have shown that some individual vitamins and vitamin-like substances e.g. coenzyme Q10 [18], B3 [19], and folate [20,21], minerals e.g. iron [22] and copper [23], and trace elements e.g. selenium [24] beneficially affect hyperlipidaemia and its complications. In these studies, effects of individual vitamins, minerals and trace elements or combination of two or three components were investigated on hyperlipidemia. Interestingly, additional food supplements prepared from plants including phytosterols appeared on the market as functional food ingredients. However, results of large clinical studies on the lipid-lowering effects of plant sterols and stanols are controversial [25,26], and it is not known if phytosterols may provide additional benefit in protection of the ischemic heart.

Dietary supplements containing multivitamins, minerals and trace elements enriched with phytosterol now are available on the market. Surprisingly, there is only very limited literature data available on the effects of such preparations developed for human use on hyperlipidemia and its consequences [27].

Therefore, here we aimed to investigate if a commercial VMTP preparation containing 17 different vitamins, coenzyme Q10, minerals, trace elements and phytosterol affects the progression of hyperlipidemia and the severity of myocardial ischemia/reperfusion injury in a diet-induced experimental model of hyperlipidemia in rats.

## Methods

This investigation conforms to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85–23, Revised 1996) and was approved by the Animal Research Ethics Committee of the University of Szeged.

Six weeks old male Wistar rats (170–200 g initial body weight) were used in the study. Animals were housed in

pairs in individually ventilated cages (Sealsafe IVC system, Italy) and were maintained in a temperature-controlled room with a 12-h:12-h light/dark cycles throughout the study. Standard rat chow and tap water were supplied ad libitum.

## Preparation of vitamins, minerals, trace elements and phytosterol (VMTP)

The VMTP preparation (“Actival Szterin film-coated tablet”, Béres Pharmaceuticals, Budapest, Hungary; for content see Table 1 and Additional file 1: Table S1) investigated in the present study is a commercially available food supplement in several countries in Europe. The individual components and their daily doses of the VMTP preparation were selected by the manufacturer on the basis of their individual preclinical and clinical efficacy and safety data available in the literature taking into consideration the Nutritive Reference Values [28].


## Experimental protocol

Male Wistar rats were fed a normal or a 2% cholesterol plus 0.25% cholic acid-enriched diet for 12 weeks to induce experimental hyperlipidemia (Figure 1). At week 0 and 8, fasting serum cholesterol as well as triglyceride measurements were performed in order to verify the development of hyperlipidemia (Figure 1). From week 8, both normolipidemic and hyperlipidemic rats were

**Table 1 Ingredients of the VMTP preparation**

Active ingredients	Amount of ingredient/ 1 g product	Daily dose*
Phytosterol	377.4 mg	39.62 mg/kg/day
Coenzim Q10	5.66 mg	0.59 mg/kg/day
Vitamin D3	1.89 µg (75.6 IU)	0.20 µg/kg/day (8 IU/kg/day)
Vitamin B1 (Thiamine)	0.42 mg	0.04 mg/kg/day
Vitamin B2 (Riboflavin)	0.53 mg	0.06 mg/kg/day
Vitamin B3 (Nicotinic acid)	6.04 mg	0.63 mg/kg/day
Vitamin B6 (Pyridoxine)	0.53 mg	0.06 mg/kg/day
Vitamin B12 (Cyanocobalamine)	0.94 µg	0.10 µg/kg/day
Biotin	18.87 µg	1.98 µg/kg/day
Pantothenic acid	2.26 mg	0.24 mg/kg/day
Folic acid	75.47 µg	7.92 µg /kg/day
Iron	2.64 mg	0.28 mg/kg/day
Manganese	0.38 mg	0.04 mg/kg/day
Copper	0.19 mg	0.02 mg/kg/day
Selenium	6.92 mg	0.73 mg/kg/day
Zinc	1.89 mg	0.20 mg/kg/day
Iodine	28.30 µg	2.97 µg/kg/day


\* To conform to the human daily dose of the preparation, rat daily dose was adjusted according to the ratio of human and rat body surface areas.




**Figure 1 Experimental protocol.** Male Wistar rats were fed with normal or 2% cholesterol and 0.25% cholic acid enriched diet to induce experimental hyperlipidemia. At week 8, fasting blood cholesterol and triglyceride measurement were performed in order to verify the development of hyperlipidemia. Both normolipidemic and hyperlipidemic rats were then fed with placebo or a mixture of vitamins, micro and trace elements (VMTP) supplemented with phytosterol for 4 weeks. At week 12, fasting blood cholesterol and triglyceride measurement were performed to monitor the effect of VMTP supplemented with phytosterol on hyperlipidemia. Hearts were then isolated, perfused according to Langendorff and subjected to a 30-min coronary occlusion followed by 120 min reperfusion to measure infarct size.

fed with a VMTP preparation (105 mg/kg/day) or placebo (57.5 mg/kg/day) for 4 weeks (Figure 1). To conform to the human daily dose of the preparation, rat daily dose was adjusted according to the ratio of human and rat body surface areas. Then fasting serum cholesterol and triglyceride measurements were performed at

week 12 to monitor the effect of multivitamin treatment on hyperlipidemia (Figure 1). At week 12, rats were anaesthetized using diethyl ether. Hearts were isolated (Figure 1), and perfused according to Langendorff as described earlier [29]. The perfused hearts were then subjected to a 30-min regional ischemia and a 120-min



**Figure 2 Effect of 2% cholesterol plus 0.25% cholic acid-enriched diet on serum cholesterol and triglyceride levels.** Serum cholesterol level at week 0 (Panel A) and week 8 (Panel C) as well as serum triglyceride level at week 0 (Panel B) and week 8 (Panel D). Values are means  $\pm$  SEM, \* $p < 0.05$  normal vs. cholesterol-enriched diet;  $n = 22$  in each group.



reperfusion. At the end of the perfusion protocol, the coronary artery was reoccluded and the area at risk and the infarcted area were delineated using an Evans blue/triphenyltetrazolium chloride double staining method [30,31] (Figure 1).

#### Measurement of serum cholesterol and triglyceride levels

To monitor the effect of 2% cholesterol plus 0.25% cholic acid-enriched diet as well as VMTP treatment on serum lipid levels, serum cholesterol and triglyceride levels were measured at week 0, 8 and 12 using a test kit supplied by Diagnosticum Zrt. (Budapest, Hungary) as described previously [6,32].

#### Ex vivo cardiac perfusions and infarct size determination

At week 12, rats were anesthetized and hearts were isolated and perfused at 37°C according to Langendorff with oxygenated Krebs-Henseleit buffer as previously described [31,33,34]. Hearts were subjected to 45 minutes of aerobic perfusion followed by test ischemia-reperfusion induced by a 30-min occlusion of the left descending coronary artery. A 3-0 silk suture was placed around the origin of the left descending coronary artery and passed through a plastic tube to form a snare. After stabilization of the heart, coronary occlusion was induced by pulling the ends of the suture taut and clamping the snare onto the epicardial surface. Reperfusion was achieved by releasing the snare as previously described [31,34] (Figure 1). At the end of the 2-h reperfusion protocol, the coronary artery was reoccluded and 5 ml of 0.1% Evans blue dye (Merck, Germany) was injected into the aorta to delineate the area-at-risk zone. Stained hearts were weighed, frozen, sliced, and incubated at 37°C in 1% triphenyl-tetrazolium chloride (Sigma Aldrich, Germany) to delineate infarcted tissue. Slices were then fixed and quantified by planimetry using Infarctsize 2.5 software (Pharmahungary, Szeged, Hungary) [32]. Infarct size was expressed as a percentage of the area-at-risk zone [30]. The area at risk was calculated as a percentage of total ventricular area [30].

#### Measurement of plasma hs-CRP and uric acid levels

Plasma hs-CRP level was measured as a systemic marker of inflammation at week 12 by a commercially available immunoturbidimetric kit from Roche Diagnostics (Mannheim, Germany) according to the instructions of the manufacturer. The functional sensitivity of hs-CRP assay was 0.11 mg/L and the measuring range was between 0.1-20 mg/L.

Plasma uric acid level was measured as a general antioxidant marker at week 12 by a colorimetric kit provided by Roche Diagnostics (Mannheim, Germany) according to the instructions of the manufacturer. The detection limit of the assay was 11.9  $\mu\text{mol/L}$  and the measuring range was between 11.9-1487  $\mu\text{mol/L}$ .

#### Statistical analysis

Statistical analysis was performed by using Sigmaplot 12.0 for Windows (Systat Software Inc). All values are presented as mean  $\pm$  SEM. Two way ANOVA was used

**Table 2 Effect of VMTP preparation on body weight, heart weight and coronary flow (CF)**

Parameter	Normolipidemia		Hyperlipidemia		Significance
	Placebo	VMTP	Placebo	VMTP	
Body weight (g)	472 ± 56	461 ± 25	480 ± 58	480 ± 35	ns
Heart weight (g)	1.59 ± 0.75	1.49 ± 0.55	1.6 ± 0.76	1.66 ± 0.90	ns
(Heart weight/body weight)*1000	3.38 ± 0.12	3.23 ± 0.17	3.33 ± 0.10	3.38 ± 0.15	ns
CF (mL/min) – before ischemia	17.4 ± 1.3	18.9 ± 1.5	19.3 ± 2.6	19.1 ± 2.2	ns
CF (mL/min) – first minute of ischemia	15.7 ± 2.1	20.3 ± 2.3	17.4 ± 4.2	19.9 ± 3.4	ns
CF (mL/min) – during ischemia	19.7 ± 1.2	20.6 ± 1.8	20.5 ± 2.3	25.2 ± 4.0	ns
CF (mL/min) - end of reperfusion	22.0 ± 5.8	16.8 ± 2.0	14.7 ± 2.2	20.3 ± 2.4	ns

to determine the effect of hyperlipidemia or VMTP on fasting serum cholesterol and triglyceride levels, plasma hs-CRP and uric acid levels, as well as on the infarct size.  $P < 0.05$  was accepted as a statistically significant difference.

## Results

### Effect of cholesterol-enriched diet on serum lipid levels

In order to verify the development of hyperlipidemia in rats fed a 2% cholesterol plus 0.25% cholic acid-enriched diet, concentrations of fasting serum triglyceride and cholesterol levels were determined at week 0 and 8 (Figure 2). Baseline serum triglyceride and cholesterol levels did not differ between groups at week 0. Cholesterol-fed rats showed a significantly higher serum cholesterol level as compared to normal rats at week 8 confirming the development of hypercholesterolemia (Figure 2C). However, serum triglyceride level was not significantly affected by cholesterol diet at week 8 (Figure 2D).

### Effect of VMTP treatment on serum lipid levels, body weight and heart weight

In order to monitor the effect of VMTP on serum lipid levels, concentrations of fasting serum triglyceride and cholesterol were determined after 4 weeks of treatment (at week 12) in both normo- and hyperlipidemic groups (Figure 3). In normolipidemic animals, VMTP treatment


did not affect serum triglyceride or cholesterol levels at week 12 (Figures 3A and 3B). In hyperlipidemic animals, VMTP treatment significantly decreased serum cholesterol level as compared to hyperlipidemic placebo-treated group at week 12 (Figure 3A), however, it did not change serum triglyceride level (Figure 3B). Body weight or heart weight was not significantly different among the experimental groups (Table 2).

### Effect of VMTP treatment on area at risk, infarct size and coronary flow

Infarct size was measured at week 12 to investigate the severity of ischemia/reperfusion injury and the effect of VMTP treatment in normolipidemia as well as in hyperlipidemia. Neither the presence of hyperlipidemia nor the VMTP treatment had a significant effect on infarct size at week 12 (Figure 4). The area-at-risk zone and coronary flow were not affected significantly in any of the groups (Figure 4, Table 2).

### Effect of VMTP preparation on plasma hs-CRP and uric acid levels

Plasma hs-CRP level was measured as a systemic endogenous marker of inflammation. Neither the presence of hyperlipidemia nor the VMTP treatment had a significant effect on plasma hs-CRP level at week 12 (Table 3). Plasma level of uric acid, a well-known antioxidant,



**Figure 4 Effect of the VMTP preparation on infarct size.** Area at risk (Panel A) and infarct size (Panel B) at week 12. Values are means ± SEM, n = 9-10.

**Table 3 Effect of VMTP preparation on plasma hs-CRP and uric acid levels**

Parameter	Normolipidemia		Hyperlipidemia		Significance
	Placebo	VMTP	Placebo	VMTP	
hs-CRP (mg/L)	1.38 ± 0.14	1.19 ± 0.19	1.31 ± 0.12	1.65 ± 0.15	ns
Uric acid (µmol/L)	42.8 ± 12.5	64.8 ± 15.1	75.3 ± 15.3	57.6 ± 11.4	ns

was not significantly different among the experimental groups (Table 3).

## Discussion

In the present study we have shown that chronic treatment of hyperlipidemic adult male rats with a VMTP preparation containing 9 vitamins, coenzyme Q10, 5 micro-, and 1 trace element and phytosterol reduces serum cholesterol, the major risk factor for cardiovascular disease. However, this preparation failed to affect the severity of ischemia/reperfusion injury. This is the first demonstration that although VMTP preparation effectively reduces cholesterol level but does not provide cardioprotection.

Regular consumption of multivitamins supplemented with coenzyme Q10 and phytosterols for prevention or adjunctive treatment of cardiovascular risk factors is common in developed countries. According to our best knowledge, there are no preclinical studies available in the literature investigating the effect of a complex preparation of multivitamins, multimineral, vitamin-like substances, and phytosterol on hyperlipidemia. Only one clinical pilot study evaluated the efficacy and safety of a similar complex preparation on serum lipid levels [27]. This study involving 25 children and adolescents with a borderline hypercholesterolemia (serum total cholesterol 180–240 mg/dL) has shown that a combination of plant sterol, fish oil and B vitamins significantly reduced serum total cholesterol, LDL-cholesterol, VLDL-cholesterol, subfractions LDL-2, IDL-1, IDL-2 and plasma homocysteine level after 16 weeks of treatment [27]. In our present study, we have shown that a commercially available VMTP preparation significantly reduced serum cholesterol level in hyperlipidemic but not in normolipidemic rats. However, it did not affect triglyceride levels in either normolipidemic or hyperlipidemic animals. These studies show that complex preparations of multivitamins and phytosterols beneficially affect the severity of hypercholesterolemia. In our present study, the VMTP preparation resulted in an approximately 25% reduction in serum cholesterol level in hyperlipidemic animals. However, clinical trials and their meta-analysis showed that phytosterol alone may result in an approximately 4–15% reduction in serum cholesterol level in hyperlipidemia [35]. Therefore, one may speculate that a combination of phytosterol with multivitamins, multimineral, and coenzyme Q10 may have an additional benefit on lipid lowering, possibly via influencing

unsaturated fatty acid levels or HMG-CoA activities. However, this assumption needs further preclinical and clinical studies.

It is well known that hyperlipidemia is a major risk factor of myocardial infarction and hyperlipidemia interferes with cardioprotective mechanisms [8]. However, interestingly there are no data available in the literature on the cardioprotective effect of any complex multivitamins. Therefore, here we investigated the effect of a VMTP preparation on myocardial infarct size and found that the VMTP preparation failed to affect infarct size in normal or cholesterol-fed animals. This is the first demonstration that a VMTP preparation although effectively reduced serum cholesterol levels it did not provide cardioprotection.

It should be mentioned that only one experimental study [36] supports the direct infarct size limiting effect of a phytosterol derivative in rats. However, there is a lack of gender distribution in the experimental population in this aforementioned study [36]. Taken together, our present study is the first demonstration that VMTP preparation effectively reduces cholesterol level but does not provide cardioprotection. Although the reason for the lack of cardioprotective effect by VMTP in our study is not known as no alterations were found in inflammatory markers and antioxidants, it seems that the VMTP preparation is not able to directly prevent necrosis in an acute model of myocardial infarction. However, it cannot be excluded that the VMTP preparation may be able to confer some cardioprotection in cases when infarct size is increased.

Our current study is limited in some aspects since it does not examine the mechanism of the effect of VMTP preparation and the individual contribution of the 17 different components and their interactions in the present model of experimental hyperlipidemia and infarction. However, it needs to be emphasized that this particular preparation and others with similar compositions (multivitamins, vitamin-like substances e.g. coenzyme Q10, multimineral, and phytosterols) are commercially available and regularly consumed by healthy population and that at risk of cardiovascular disease. Therefore, thorough investigations of the efficacy and safety of such products are important in cardiovascular risk. Future studies investigating the possible preventive effect of VMTP preparations on the development of hyperlipidemia are also needed.

## Conclusions

Although VMTP preparations are widely used in healthy population or by patients with cardiovascular risk factors including hyperlipidemia, our present study is the first preclinical demonstration that a VMTP preparation attenuates the progression of experimental hypercholesterolemia, however, it does not affect the severity of ischemia/reperfusion injury in the heart. Further preclinical and clinical studies are needed to optimize the compositions and to elucidate the efficacy, safety and the mechanism of the effect of widely used VMTP preparations.

## Additional file

**Additional file 1: Table S1.** Ingredients of the Placebo.

## Competing interests

Béres Pharmaceuticals Ltd. was the leader of the consortial project funded by the National Development Agency (MED\_FOOD TECH\_08-A1-2008-0275).

## Author contributions

TC, CK and PF conception and design of research; MS, GS, RG, PB, CS, JB and IF performed experiments; MS, GS, PB, RG, CS, JB and CC analysed data; MS, GS, JB, IF and TC interpreted results of experiments; MS prepared figures; TC, and MS drafted manuscript; MS, TC and PF edited and revised manuscript; TC, MS, GS, CS, JB, PB, RG, CC, IF, CK and PF approved final version of manuscript.

## Acknowledgments

This work was supported by grants from the National Development Agency (MED\_FOOD TECH\_08-A1-2008-0275, Baross DA-TECH-07-2008-0041, TÁMOP-4.2.1/B-09/1/KONV-2010-0005, TÁMOP-4.2.2/B-10/1-2010-0012, TÁMOP-4.2.2.A-11/1/KONV-2012-0035), the Hungarian Scientific Research Fund (OTKA K79167), and co-financed by the European Regional Development Fund and VÁTI Hungarian Nonprofit LLC for Regional Development and Town Planning (HURO/0901/137/2.2.2-HU-RO-TRANS-MED). T. Csont held a "János Bolyai Fellowship" of the Hungarian Academy of Sciences. M. Sarkozy and G. Szucs hold a "Jedlik Ányos Predoctoral Fellowship". This research was realized in the frames of TÁMOP 4.2.4. A/2-11-1-2012-0001 National Excellence Program – Elaborating and operating an inland student and researcher personal support system. The project was subsidized by the European Union and co-financed by the European Social Fund. M. Sarkozy holds a "Talent Publication Support from the University of Szeged, 2012/2013". We acknowledge the technical support of Judit Pipis for blood sampling and serum insulin measurements.

## Author details

<sup>1</sup>Cardiovascular Research Group, Department of Biochemistry, Faculty of Medicine, University of Szeged, Szeged, Hungary. <sup>2</sup>Pharmahungary Group, Szeged, Hungary. <sup>3</sup>Béres Pharmaceuticals Ltd, Budapest, Hungary.

<sup>4</sup>Department of Laboratory Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary. <sup>5</sup>Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

Received: 30 July 2013 Accepted: 13 September 2013

Published: 25 September 2013

## References

1. Kuklina EV, Yoon PW, Keenan NL: Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. *JAMA* 2009, **302**:2104–2110.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB: American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association. *Circulation* 2012, **125**:188–197.
3. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. *JAMA* 1987, **257**:2176–2180.
4. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack CV Jr, Gore JM, Chandra-Strobo N, Peterson ED, French WJ: Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J* 2008, **156**:1026–1034.
5. Varga ZV, Kupai K, Szucs G, Gaspar R, Paloczi J, Farago N, Zvara A, Puskas LG, Razga Z, Tiszlavicz L, Bencsik P, Gorbe A, Csonka C, Ferdinandy P, Csont T: MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. *J Mol Cell Cardiol* 2013, **62**:111–121.
6. Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A, Csonka C, Puskas LG, Santha M, Ferdinandy P: Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. *Cardiovasc Res* 2007, **76**:100–109.
7. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, Szentgyorgyi R, Nagy I, Koltai M, Dux L: Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. *J Mol Cell Cardiol* 1997, **29**:3321–3333.
8. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. *Pharmacol Rev* 2007, **59**:418–458.
9. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P: Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. *Chest* 2005, **128**:1623–1628.
10. Kupai K, Csonka C, Fekete V, Odendaal L, Van Rooyen J, Marais De W, Csont T, Ferdinandy P: Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. *Am J Physiol Heart Circ Physiol* 2009, **297**:H1729–1735.
11. Schuck RN, Mendys PM, Simpson RJ Jr: Beyond statins: lipid management to reduce cardiovascular risk. *Pharmacotherapy* 2013, **33**:754–764.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987, **317**:1237–1245.
13. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* 1986, **8**:1245–1255.
14. Li K, Kaaks R, Linseisen J, Rohrmann S: Vitamin/mineral supplementation and cancer, cardiovascular, and all-cause mortality in a German prospective cohort (EPIC-Heidelberg). *Eur J Nutr* 2012, **51**:407–413.
15. Bailey RL, Fulgoni VL, Keast DR, Dwyer JT: Examination of vitamin intakes among US adults by dietary supplement use. *J Acad Nutr Diet* 2012, **112**:657–663.
16. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF: Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. *Am J Epidemiol* 2004, **160**:339–349.
17. Beitz R, Mensink GB, Fischer B, Thamm M: Vitamins–dietary intake and intake from dietary supplements in Germany. *Eur J Clin Nutr* 2002, **56**:539–545.
18. Yuvaraj S, Premkumar VG, Vijayarathy K, Gangadaran SG, Sachdanandam P: Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. *Clin Biochem* 2007, **40**:623–628.
19. Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovick R, Cohen R, Hayek T: Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. *Am J Med Sci* 2013, **345**:195–199.
20. Lim HJ, Choi YM, Choue R: Dietary intervention with emphasis on folate intake reduces serum lipids but not plasma homocysteine levels in hyperlipidemic patients. *Nutr Res* 2008, **28**:767–774.

21. Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A: **Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial.** *Arch Med Res* 2009, **40**:380–386.
22. Dabbagh AJ, Shwaery GT, Keaney JF Jr, Frei B: **Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit.** *Arterioscler Thromb Vasc Biol* 1997, **17**:2638–2645.
23. Galhardi CM, Diniz YS, Rodrigues HG, Faine LA, Burneiko RC, Ribas BO, Novelli EL: **Beneficial effects of dietary copper supplementation on serum lipids and antioxidant defenses in rats.** *Ann Nutr Metab* 2005, **49**:283–288.
24. Poirier J, Cockell K, Hidioglou N, Madere R, Trick K, Kubow S: **The effects of vitamin E and selenium intake on oxidative stress and plasma lipids in hamsters fed fish oil.** *Lipids* 2002, **37**:1125–1133.
25. Talati R, Sobieraj DM, Makanji SS, Phung OJ, Coleman CI: **The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis.** *J Am Diet Assoc* 2010, **110**:719–726.
26. Laitinen K, Gylling H: **Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence.** *Lipids Health Dis* 2012, **11**:140–511. X-11-140.
27. Garaiova I, Muchova J, Nagyova Z, Mislanova C, Oravec S, Dukat A, Wang D, Plummer SF, Durackova Z: **Effect of a plant sterol, fish oil and B vitamin combination on cardiovascular risk factors in hypercholesterolemic children and adolescents: a pilot study.** *Nutr J* 2013, **12**:7–2891. 12-7.
28. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011. *Off J Eur Union*. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:304:0018:0063:EN:PDF>.
29. Csont T, Balogh G, Csonka C, Boros I, Horvath I, Vigh L, Ferdinandy P: **Hyperlipidemia induced by high cholesterol diet inhibits heat shock response in rat hearts.** *Biochem Biophys Res Commun* 2002, **290**:1535–1538.
30. Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, Csont T, Ferdinandy P: **Measurement of myocardial infarct size in preclinical studies.** *J Pharmacol Toxicol Methods* 2010, **61**:163–170.
31. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, Giricz Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P: **Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts.** *Am J Physiol Heart Circ Physiol* 2008, **294**:H2406–2409.
32. Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis GF, Pipis J, Szucs G, Csonka C, Puskas LG, Ferdinandy P, Csont T: **Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats.** *Cardiovasc Diabetol* 2013, **12**(16):12–16.
33. Ferdinandy P, Csonka C, Csont T, Szilvassy Z, Dux L: **Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide.** *Mol Cell Biochem* 1998, **186**:27–34.
34. Kocsis GF, Sarkozy M, Bencsik P, Pipicz M, Varga ZV, Paloczi J, Csonka C, Ferdinandy P, Csont T: **Preconditioning protects the heart in a prolonged uremic condition.** *Am J Physiol Heart Circ Physiol* 2012, **303**:H1229–1236.
35. Gupta AK, Savopoulos CG, Ahuja J, Hatzitolios AI: **Role of phytosterols in lipid-lowering: current perspectives.** *QJM* 2011, **104**:301–308.
36. Zhang S, Li H, Yang SJ: **Tribulosin protects rat hearts from ischemia/reperfusion injury.** *Acta Pharmacol Sin* 2010, **31**:671–678.

doi:10.1186/1476-511X-12-138

**Cite this article as:** Csont et al.: Effect of a multivitamin preparation supplemented with phytosterol on serum lipids and infarct size in rats fed with normal and high cholesterol diet. *Lipids in Health and Disease* 2013 **12**:138.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

